BioTuesdays

Tag - Maxim Group

ayala logo
Markets

Maxim lowers Ayala Pharma PT to $12 from $22

Maxim Group reduced its price target for Ayala Pharmaceuticals (NASDAQ:AYLA) to $12 from $22, but maintained a “buy” rating, after the company discontinued the Phase 2 TENANCITY trial evaluating AL101 in triple negative...

March 30, 2022
Longeveron
Markets

Maxim starts Longeveron at buy; PT $14

Maxim Group initiated coverage of Longeveron (NASDAQ:LGVN) with a “buy” rating and $14 price target. The stock closed at $6.52 on March 23. Longeveron is developing a medicinal signaling cell therapy, Lomecel-B, for...

March 24, 2022
HCW Biologics
Markets

Maxim starts HCW Biologics at buy; PT $4

Maxim Group initiated coverage of HCW Biologics (NASDAQ:HCWB) with a “buy” rating and price target of $4. The stock closed at $2.28 on March 23. HCW Biologics is addressing inflammaging; the chronic, sterile, low-grade...

March 24, 2022
Unicycive Therapeutics
Markets

Maxim starts Unicycive Therapeutics at buy; PT $3

Maxim Group initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a “buy” rating and price target of $3. The stock closed at $1.07 on March 15. Unicycive is aiming to bring two key assets through clinical...

March 16, 2022
NexGel
Markets

Maxim starts NexGel at buy; PT $6

Maxim Group initiated coverage of NexGel (NASDAQ:NXGL) with a “buy” rating and a price target of $6. The stock closed at $1.81 on Feb. 24. NexGel manufactures, develops, and commercializes topical hydrogel-based...

February 25, 2022
SeqLL
Markets

Maxim starts SeqLL at buy; PT $3

Maxim Group initiated coverage of SeqLL (NASDAQ:SQL) with a “buy” rating and price target of $3. The stock closed at $1.60 on Feb. 8. SeqLL is developing true single molecule sequencing (tSMS), a type of short-read...

February 9, 2022
Kiora Logo
Markets

Maxim starts Kiora Pharma at buy; PT $2.50

Maxim Group initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $2.50. The stock closed at 80 cents on Jan. 18. Kiora is developing ophthalmic medicines including, KIO-101...

January 19, 2022
INVO Bioscience
Markets

Maxim starts INVO Bioscience at buy; PT $7

Maxim Group launched coverage of INVO Biosciences (NASDAQ:INVO) with a “buy” rating and $7 price target. The stock closed at $3.69 on Jan. 18. INVO is a commercial-stage company with the world’s first and only...

January 19, 2022
Markets

Maxim ups Daré Biosciences PT to $4 from $3

Maxim Group raised its price target for Daré Bioscience (NASDAQ:DARE) to $4 from $3, citing FDA approval of XACIATO vaginal gel as a treatment for bacterial vaginosis (BV) and a commercial launch in 2022. The stock...

January 18, 2022